Members of "http://www.berenice-project.eu/" BERENICE consortium about Chagas' disease, led by Dr. Israel Molina, researcher of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), had their Third General Assembly on the 28th January 2015, in Barcelona. The main objective of the meeting was to discuss with its eight European and Latin American partners the progress of the project, which began on 1st September 2013, for a period of 5 years. BERENICE is funded under the European Community's 7th Framework Programme with the aim to obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease.During the meeting, the partners shared updates on project progress to date and discussed how to move forward both at Work Package and Consortium levels. The project is in a key moment to decide the final formulation to conduct clinical trials in humans. It is designed as an international multicenter clinical trial which will take place in the facilities of the Vall Hebron University Hospital and other sites such as Argentina, Bolivia or Mexico.The encapsulation of benznidazole using nanotechnology will generate a new drug delivery system. This new approach will allow a release of medication directly into the intracellular space, therefore increasing tissue drug concentration and avoiding side effects. A better toxic profile will be obtained because of the reduced amount of benznidazole used.